PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Evaluation of influence of systemie adjuvant chemotherapy applied according to modified scheme MVAC on survival of patients treated for invasive bladder cancer
Article published in Urologia Polska 2002/55/1.

authors

Wojciech Kołaczyk 1, Janusz Dembowski 2, Jerzy Lorenz 2, Krzysztof Dudek 3
1 Oddział Urologii Szpitala Wojewódzkiego w Legnicy
Ordynator oddziału: dr Wojciech Kołaczyk
2 Katedra i Klinika Urologii Akademii Medycznej we Wrocławiu
Kierownik kliniki: prof, dr hab. Jerzy Lorenz
3 Zakład Inżynierii Niezawodności i Diagnostyki Politechniki we Wrocławiu

keywords

bladder, invasive bladder cancer, systemie chemotherapy

summary

Purpose. The aim of the paper was assesement of influence of adjuvant systemic chemotherapy applied according to modified
scheme MVAC in patients treated for invasive bladder cancer. Materials and methods. We retrospectively reviewed two groups: the first one included patients who received chemotherapy
Group A - 26) after cystectomy, and second one included patients treated only with surgery (Group K-62 patients). The average time of observation was 3,2 years (aximum 10 years 3 months, minimum 3 months). The patients in main group were divided into two subgroups: the first one included patients where tumour was confined to bladder (Tl+T2+T3a), and the second was made up the remaining patients where tumor expanded behind the bladder (T3b+T4a+b
The Results. In Group A we didn\'t observe survival rate longer than 5 years. The survival rate in Group K was 57,4% wheras in Group A - 41,4%. We didn\'t observe statistical differences in survival rate in patients with changes in lymph nodes. In group of patients without changes in lymph nodes and where tumour was confined to bladder, 5 years survival in the Group A was 51,4%, whereas in Group K- 93%.
Conclusion. Systemic adjuvant chemotherapy does not influence the survival of patients treated for invasive bladder cancer.

references

  1. 1. Angulo JC, Sanchez-Chapado M, Grignon DJ, Montic JE. Pontes EJ: Radical cystectomy in node positive bladder cancer. Multivariate analysis on prognostic factors. Eur Urol 1996; 30 S2, 267, abstr. 1003.
  2. 2. Ashamallah A, El-Mekresh MM, El-Baz MA, Elatar IA, Gho-neini MA: Radical cystectomy for carcinoma of the urinary bladder: critical evaluation of the results in 1026 cases. Brit J Urol, 1997, 49, abstr. 190.
  3. 3. Dinney CPN, Perrotte P, Slaton JW: Impact of adjuvant chemotherapy on longterm survival ofpatints with lymph node metastases after radical cystectomy. J Urol 159; 5; 166, abstr. 635.
  4. 4. Freiha F, Reese J, Torti FM: A randomised trial of radical cyslectomy and radical cystectomy plus cisplalin, vinblastine, and methotrexate chemoierapy for muscle invasive bladder cancer. J Urol 1996; 155; 495-500.
  5. 5. Logothetis C, Johnson DE, Chong C, Dexeus FH, Sella A, Ogden S, Smith T, Swanson DA, Babaian RJ, Wishnow KI, Eschenbach von AC: Adjuvant cyclophosphamide, doxorubicin and cisplalin chemotherapy for bladder cancer: an update. J Clin Oncol 1988; 6; 1560,
  6. 6. Logolhetis C, Swanson D, Amato R: Optimal delivery of perioperative chemotherapy: Preliminary results of randomized, prospective comperative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma. Cancer 1992; 69; 2767-2769,
  7. 7. Otlo T, Boergmann C, Krege S, Ruebben II and Participating Clinicans: Adjuvant chemotherapy in locally advanced bladder cancer [PT3/PN1-2, MO] a phase III study. Eur Urol 2001; (suppl 5); 147.
  8. 8. Ruebben H, Otto T: Loka! forigeschrittenes oder metastusiertes Hamblasencarcinom. Urologie 2001: 40; 464-467.
  9. 9. Schulz-Lampel D, Lampel A: Neo-adjuvant and adjuvant treatment for locally invasive bladder cancer. Cur Op Urol 1999; 9; 419-424.
  10. 10. Skinner DG, Daniels R, Russel CA, Leiskovsky G, Boyd SD, Nichols P, Kern W, Sakamoto J, Krailo M, Groshen S: The role adjuvant chemotherapy following cystectomy for invasive bladder cancer: prospective trial. J Urol 1991; 145; 459-467.
  11. 11. Skinner DG, Slein JR Leiskovsky G, Skinner EC, Boyd SD, Fi-gucroa A, Jones P, Cole R, Groshen S: 25-year experience in the management of invasive bladder cancer by radical cystectomy. Eur Urol 1998; 33 (suppl. 4); 25-26.
  12. 12. Stoeckle M, Mcyenburg M, Wellek S et al: Advanced bladder cancer (stages pT3b, pT4a, pNl and pN2): improved survival after radical cystectomy and 3 adjuvant cycles chemotherapy. Results of a controlled prospective study. J Urol 1992; 148; 302-307.
  13. 13. Sluder UE, Bacchi M, Biedermann C: Adjuvant cisplalin chemotherapy following cystectomy for bladder cancer. Results of a prospective randomised trial. J Urol 1994; 152; 81-84.
  14. 14. Wei Chih-Hsin, Hsieh Ruey-Kucn, Chiou Tzeon-Jye, Chen Kuang-Kuo, Chang Luke S, Chen Po-Min: Adjuvant methotrexate, vinblastine and cisplalin chemotherapy for invasive transitional cell carcinoma: Taiwan experience. J Urol 1996; 155; 118-121.
  15. 15. Woehr M, Echtle D, Westermann D, Kontaxis D, Mueller E, Frohneberg D: Survival, lypmph node status and adjuvant chemotherapy. Eur Urol 2001 (suppl 5); 145.

correspondence

Wojciech Kolaczyk
Szpital Wojewódzki Oddział Urologii
ul. Iwaszkiewicza 5
76 - 866 Legnica